Next, to determine whether biomarkers in the setting of metformin treatment may be predictive of prostate cancer recurrence, we evaluated the radical prostatectomy specimens from the 49 patients who were treated with metformin for TWIST1, N-cadherin, p-p65 and p-AMPK immunoreactivity (Fig. S1). Here, TWIST1 is linked to Familial prostate cancer.